

Sabine Grimm

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3437178/publications.pdf>

Version: 2024-02-01

26
papers

429
citations

840585

11
h-index

752573

20
g-index

28
all docs

28
docs citations

28
times ranked

963
citing authors

#	ARTICLE	IF	CITATIONS
1	Mogamulizumab for Previously Treated Mycosis Fungoides and SÅ©zary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2022, 40, 509-518.	1.7	1
2	Lenalidomide with Rituximab for Previously Treated Follicular Lymphoma and Marginal Zone Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2021, 39, 171-180.	1.7	4
3	Building a trusted framework for uncertainty assessment in rare diseases: suggestions for improvement (Response to "TRUST4RD: tool for reducing uncertainties in the evidence generation for) Tj ETQq1.1 0.7843i14 rgBT	1.1	1
4	High-sensitivity troponin assays for early rule-out of acute myocardial infarction in people with acute chest pain: a systematic review and economic evaluation. <i>Health Technology Assessment</i> , 2021, 25, 1-276.	1.3	16
5	State of the ART? Two New Tools for Risk Communication in Health Technology Assessments. <i>Pharmacoeconomics</i> , 2021, 39, 1185-1196.	1.7	4
6	Exploring the Feasibility of Comprehensive Uncertainty Assessment in Health Economic Modeling: A Case Study. <i>Value in Health</i> , 2021, 24, 983-994.	0.1	7
7	Filgotinib for Moderate to Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2021, 39, 1397-1410.	1.7	3
8	Implementation Barriers to Value of Information Analysis in Health Technology Decision Making: Results From a Process Evaluation. <i>Value in Health</i> , 2021, 24, 1126-1136.	0.1	4
9	Optimizing the Use of High-Sensitivity Troponin Assays for the Early Rule-out of Myocardial Infarction in Patients Presenting with Chest Pain: A Systematic Review. <i>Clinical Chemistry</i> , 2021, 67, 237-244.	1.5	17
10	Development and Validation of the TRansparent Uncertainty ASsessment (TRUST) Tool for Assessing Uncertainties in Health Economic Decision Models. <i>Pharmacoeconomics</i> , 2020, 38, 205-216.	1.7	23
11	Cost assessment of health interventions and diseases. <i>RMD Open</i> , 2020, 6, e001287.	1.8	11
12	Cost-effectiveness of Digital Breast Tomosynthesis in Population-based Breast Cancer Screening: A Probabilistic Sensitivity Analysis. <i>Radiology</i> , 2020, 297, 40-48.	3.6	15
13	Health technology assessment: a framework. <i>RMD Open</i> , 2020, 6, e001289.	1.8	17
14	Steps in implementing a health economic evaluation. <i>RMD Open</i> , 2020, 6, e001288.	1.8	5
15	Patient engagement in health technology assessment (HTA) and the regulatory process: what about rheumatology?. <i>RMD Open</i> , 2020, 6, .	1.8	1
16	Clinically inappropriate post hoc exclusion of study participants from test accuracy calculations: the ROMA score, an example from a recent NICE diagnostic assessment. <i>Annals of Clinical Biochemistry</i> , 2019, 56, 72-81.	0.8	1
17	Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2019, 37, 1195-1207.	1.7	8
18	Arsenic Trioxide for Treating Acute Promyelocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2019, 37, 887-894.	1.7	13

#	ARTICLE	IF	CITATIONS
19	Nivolumab for Treating Metastatic or Unresectable Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2019, 37, 655-667.	1.7	8
20	Estimating Future Health Technology Diffusion Using Expert Beliefs Calibrated to an Established Diffusion Model. <i>Value in Health</i> , 2018, 21, 944-950.	0.1	11
21	EQ-5D-5L versus EQ-5D-3L: The Impact on Cost Effectiveness in the United Kingdom. <i>Value in Health</i> , 2018, 21, 49-56.	0.1	71
22	EMA and NICE Appraisal Processes for Cancer Drugs: Current Status and Uncertainties. <i>Applied Health Economics and Health Policy</i> , 2018, 16, 429-432.	1.0	12
23	Risk scores to guide referral decisions for people with suspected ovarian cancer in secondary care: a systematic review and cost-effectiveness analysis. <i>Health Technology Assessment</i> , 2018, 22, 1-264.	1.3	106
24	Assessing the Expected Value of Research Studies in Reducing Uncertainty and Improving Implementation Dynamics. <i>Medical Decision Making</i> , 2017, 37, 523-533.	1.2	17
25	The HTA Risk Analysis Chart: Visualising the Need for and Potential Value of Managed Entry Agreements in Health Technology Assessment. <i>Pharmacoeconomics</i> , 2017, 35, 1287-1296.	1.7	38
26	When Future Change Matters: Modeling Future Price and Diffusion in Health Technology Assessments of Medical Devices. <i>Value in Health</i> , 2016, 19, 720-726.	0.1	11